Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells f